Researchers discover placental stem cells that can regenerate heart after heart attack

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from the placenta known as Cdx2 cells can regenerate healthy heart cells after heart attacks in animal models. The findings, published in the May 20 issue of Proceedings of the National Academy of Sciences (PNAS), may represent a novel treatment for regenerating the heart and other organs. "Cdx2 cells have historically been thought to only generate the placenta...

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

PANASH Trial will Evaluate Safety and Early Signs of Efficacy of HepaStem® in F3- F4-grade NASH Patients Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced the dosing of a first patient in a Phase 2a clinical study for the company’s HepaStem development program in patients with  late stage non-alcoholic steatohepatitis (NASH). The multicenter, open-label PANASH study will evaluate the safety and preliminary  efficacy of Promethera’s...

Artificial embryos created from skin cells possible after breakthrough at Hebrew University of Jerusalem

New Research from the Hebrew University of Jerusalem has found a way way to transform skin cells into the three stem cell types that make up an early-stage embryo. This discovery paves a path towards creating an embryo without the need for an egg or sperm. Speaking to The Jerusalem Post, corresponding author on the new study, Yosef Buganim, said that the science is still likely decades away from replicating the process in...

Orchard Therapeutics Begins Early Trials for Genetic Treatments of Wiskott-Aldrich Syndrome and Beta-Thalassemia

Orchard Therapeutics has begin proof of concept trials for two separate rare diseases for which the current standard of care is quite poor. The first therapy is called OTL-103, and it is an autologous hematopoietic stem cell gene therapy for Wiskott-Aldrich Syndrome (WAS). WAS is a life threatening immune disorder and the current standard of care is a bone marrow transplant, which carries a high risk for mortality. Orchard Therapeutics...

University of Bristol invents surgical stem cell ‘glue’ for healing difficult, chronic wounds

Scientists at the University of Bristol have invented a new technology that could lead to a new generation of smart surgical glues and dressings for chronic wounds. The new method involves re-engineering the membranes of stem cells to effectively "weld" the cells together. The team modified the membrane of human mesenchymal stem cells ( hMSCs ) with thrombin, an enzyme that is involved in the wound healing process. The modified cells were placed...

Study reveals large differences between stem cells grown on different bio-materials – potentially skewing previous stem cell research

Researchers at the Donnelly Centre for Cellular and Biomolecular Research at the University of Toronto have found an interesting quirk in Stem Cells - their genetic expression can be highly influenced by the medium they are cultured / grown on. The U of T researchers used CRISPR technology to study which genes are essential for embryonic stem cell proliferation, and created a new technique to switch genes on and off. In the process,...

Revised CAR-T therapy eliminates dangerous cytokine release syndrome in lymphoma trial

Autologous CAR-T treatments for leukemia and lymphoma have offered new hope for patients, but the cell therapies can cause a dangerous immune reaction called cytokine release syndrome (CRS). Researchers at the University of Southern California (USC) Norris Comprehensive Cancer Center have designed a new type of CAR-T therapy to eliminate that side effect. CRS is a systemic inflammatory response that can be a life threatening side effect of various cancer and immune therapies....

St. Jude publishes results of Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency (‘bubble boy disease’)

St. Jude Children's research hospital has published the results of a lentiviral gene therapy for XSCID, showing early signs of robust improvements in the immune system of 8 patients, ranging from months old to 2 years old, in a pilot study of a gene transfer therapy. XSCID, AKA X-Linked Severe Combined Immunodeficiency is the result of a mutated chromosome, which can be either be inherited or naturally occurring. The mutation results in an immune...